Fidelity Investments’s Elicio Therapeutics ELTX Stock Holding History

Fidelity Investments’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$485	Buy	+124	New	+$1.25K	﹤0.01%	5314
2025 Q2	–	Sell	-185	Closed	-$1.14K	–	5372
2025 Q1	$1.14K	Buy	+185	New	+$1.43K	﹤0.01%	4946
2022 Q3	–	Sell	-69	Closed	-$1K	–	4986
2022 Q2	$1K	Sell	69 -29	-30%	-$463	﹤0.01%	4698
2022 Q1	$2K	Buy	98 +38	+63%	+$858	﹤0.01%	4645
2021 Q4	$2K	Sell	60 -31,190	-100%	-$1.58M	﹤0.01%	3998
2021 Q3	$3.05M	Hold	31,250	–	–	﹤0.01%	2475
2021 Q2	$4.07M	Hold	31,250	–	–	﹤0.01%	2395
2021 Q1	$5.65M	Buy	+31,250	New	+$6.03M	﹤0.01%	2225

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Fidelity Investments's ELTX Position: Q2 2026 in Review

Fidelity Investments opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 124 shares worth $485. The stake represents ﹤0.01% of the portfolio and ranks #5314 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in ELTX as recently as Q1 2025.

Fidelity Investments first reported a position in ELTX in Q1 2021 and has held it in 8 quarters since. The position peaked at $5.65M in Q1 2021. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Fidelity Investments held 124 shares of Elicio Therapeutics worth $485 as of Q2 2026.
Elicio Therapeutics was a new Fidelity Investments position in Q2 2026.
Elicio Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5314 holding.
Fidelity Investments first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 8 quarters since.
Fidelity Investments's Elicio Therapeutics position peaked at $5.65M in Q1 2021.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.